Vir Biotechnology (VIR)

Vir’s infectious disease work includes investigational programs for hepatitis delta virus, a severe form of viral hepatitis that occurs in people infected with hepatitis B. Its HDV regimen pairs tobevibart, a monoclonal antibody, with elebsiran, an RNA interference candidate, as the company seeks to address a disease with limited treatment options. Vir has also worked on antibody-based approaches for other viral diseases, including HIV, where long-acting and immune-directed therapies remain a major area of research.

In oncology, Vir applies its antibody engineering capabilities and proprietary PRO-XTEN masking platform to create candidates intended to improve tumor targeting while limiting activity in healthy tissue. Programs such as VIR-5500, VIR-5818, and VIR-5525 reflect its push beyond infectious disease into solid tumors, where differentiated biologic design can be central to clinical success.

The company does not operate like a mature pharmaceutical manufacturer with a broad portfolio of approved products. Revenue can come from collaborations, licensing arrangements, grants, and other partnership-related sources, while the investment case depends heavily on clinical trial outcomes, regulatory progress, scientific execution, and capital allocation. Vir is therefore best understood as a research-driven biotech platform with a pipeline spanning virology, immunology, and cancer biology.